On November 21, 2024, Antony Riley, the Chief Financial Officer of Forte Biosciences Inc, purchased 22,514 shares of the company. Following this transaction, the insider now owns a total of 30,776 shares. The transaction details are available in the SEC Filing. Forte Biosciences Inc (FBRX, Financial) is a clinical-stage biopharmaceutical company focused on developing therapies for inflammatory skin diseases. The company's lead product candidate is FB-401, which is being developed for the treatment of atopic dermatitis. The recent purchase by Antony Riley is part of a broader trend of insider buying at Forte Biosciences Inc. Over the past year, there have been five insider purchases and no insider sales, indicating a positive sentiment among the company's insiders. On the day of the recent purchase, shares of Forte Biosciences Inc were trading at $5.55 each, resulting in a market cap of $23.392 million. Investors may consider this insider buying activity as a potential indicator of confidence in the company's future prospects. For more information on the company's valuation metrics, such as GF Value, price-earnings ratio, price-sales ratio, price-book ratio, and price-to-free cash flow, investors can explore further details on the company's profile.
This article, generated by GuruFocus, is designed to provide general insights and is not tailored financial advice. Our commentary is rooted in historical data and analyst projections, utilizing an impartial methodology, and is not intended to serve as specific investment guidance. It does not formulate a recommendation to purchase or divest any stock and does not consider individual investment objectives or financial circumstances. Our objective is to deliver long-term, fundamental data-driven analysis. Be aware that our analysis might not incorporate the most recent, price-sensitive company announcements or qualitative information. GuruFocus holds no position in the stocks mentioned herein.
